Varian Medical Systems Inc

Most Recent

  • uploads///valuation
    Company & Industry Overviews

    How Hologic’s Valuation Stacks Up with Peers

    The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.

    By Sarah Collins
  • uploads///hospital _
    Company & Industry Overviews

    A Look at Hologic Stock’s Recent Performance

    Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.

    By Sarah Collins
  • uploads///part
    Company & Industry Overviews

    Danaher Corporation’s Excess Returns Fail to Impress

    Earlier in this series, we looked at Danaher’s return on invested capital on a standalone basis. However, we were only looking at half the story.

    By Shannon Black
  • uploads///HALCYON
    Company & Industry Overviews

    Varian’s Halcyon Treatment System Sees Emerging Market Demand

    Halcyon The Halcyon system, Varian Medical Systems’ (VAR) recently launched cancer treatment device, aims to simplify and enhance IMRT (image-guided volumetric intensity modulated radiotherapy). The device has received clearance by the FDA (US Food and Drug Administration). By next year, Varian expects to receive regulatory approvals for the device in China and Japan. For more information […]

    By Sarah Collins
  • uploads///VAR FCF
    Earnings Report

    What to Expect from Varian’s Bottom Line in Q4 2018

    Varian Medical Systems (VAR) is expected to report net income of $105.05 million in the fourth quarter of fiscal 2018.

    By Kenneth Smith
  • uploads///VAR
    Company & Industry Overviews

    Here’s What Varian Medical Systems’ Valuation Trend Indicates

    Of the nine analysts covering Varian Medical Systems (VAR) stock, three have given it a “strong buy,” three have given it a “hold,” and three have given it a “sell.”

    By Kenneth Smith
  • uploads///VAR
    Company & Industry Overviews

    Understanding Varian Medical Systems’ Business Segments

    Revenues from the Oncology Systems segment increased from $564.4 million in fiscal Q3 2017 to $667.2 million in fiscal Q3 2018.

    By Kenneth Smith
  • uploads///mri _
    Company & Industry Overviews

    Why ViewRay Stock Fell 9.4% on August 3

    On August 3, ViewRay (VRAY) reported revenues of $16.4 million for Q2 2018, which is a YoY rise of 2,248.6%.

    By Margaret Patrick
  • uploads///checklist _
    Earnings Report

    How Baxter International Fared in the Second Quarter

    Baxter’s gross profit increased from $1.13 billion in Q2 2017 to $1.24 billion in Q2 2018.

    By Kenneth Smith
  • uploads///aerial view _
    Earnings Report

    What to Expect from Varian Medical Systems’ Q3 2018 Earnings

    Varian Medical Systems (VAR) is expected to report its Q3 2018 earnings on July 25. Analysts expect its revenues to increase 0.30%.

    By Kenneth Smith
  • uploads///VAR
    Company & Industry Overviews

    Insights on Varian’s Acquisition Deal with Sirtex Medical

    On January 30, Varian Medical Systems (VAR) entered into an agreement to acquire Australian company Sirtex Medical for $1.2 billion, at 28 Australian dollars per share.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Varian’s HyperArc: Driven by Rising Metastatic Brain Cancer?

    Varian Medical Systems’ (VAR) HyperArc is an end-to-end, high-definition, intracranial radiotherapy solution.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Varian Medical Systems and International Market Penetration

    In 1Q18, Varian Medical Systems (VAR) reported revenues of $356.7 million from the Americas region, which was a YoY (year-over-year) growth of 20%.

    By Margaret Patrick
  • uploads///DEAL RATIONALE
    Company & Industry Overviews

    Rationale behind Varian Medical’s Acquisition of Sirtex Medical

    On January 30, 2018, Varian Medical Systems (VAR) announced that it had entered into an agreement to acquire Sirtex Medical Limited for $1.3 billion.

    By Sarah Collins
  • uploads///EPS ESTIMATES
    Earnings Report

    ZBH’s 4Q17 Earnings Results Meet Analysts’ Estimates

    Zimmer Biomet Holdings announced its 4Q17 and 2017 results on January 30. The company’s sales exceeded analysts’ estimates, while its adjusted earnings per share managed to meet estimates.

    By Sarah Collins
  • uploads///GUIDANCE
    Earnings Report

    Will Varian Medical Systems’ Sales Decline Again in 1Q18?

    According to Wall Street analysts’ estimates, Varian Medical Systems (VAR) will report revenues of $636.8 million in 1Q18, a YoY decline of 16.6%.

    By Sarah Collins
  • uploads///objectives
    Company & Industry Overviews

    A Look at Varian Medical Systems’ Long-Term Objectives

    Varian Medical Systems (VAR) spun off its imaging components business into Varex Imaging in January 2017, thus strengthening its positioning in the oncology market.

    By Sarah Collins
  • uploads///part  nd
    Consumer

    Healthcare Was September Loser for US Domestic Moats

    The healthcare sector has been the most challenged sector since the presidential elections in November 2016.

    By VanEck
  • uploads///stock price
    Company & Industry Overviews

    Intuitive Surgical’s Recent Stock Split: The Market Reaction

    On October 6, 2017, Intuitive Surgical will start trading on a split-adjusted basis. It has scheduled a stock split for its shares in a ratio of 3:1.

    By Sarah Collins
  • uploads///PROTON THERAPY
    Company & Industry Overviews

    How Varian Is Harnessing Proton Therapy Market Opportunities

    Proton therapy market opportunities The proton therapy market is a highly lucrative opportunity area for Varian Medical Systems (VAR). Proton therapy uses protons for treating cancer instead of X-rays. According to a Medgadget report, the global proton therapy market is expected to double by the year 2022. Though the United States has the biggest proton […]

    By Sarah Collins
  • uploads///profitability drivers
    Company & Industry Overviews

    Why Varian Medical Systems’ Profitability Is Improving

    Varian Medical Systems’ profitability In 3Q17, Varian Medical Systems reported a gross margin of approximately 44.5%, representing an 18-basis-point improvement in the quarter. YTD (year-to-date), the margin has improved by around 138 basis points. In 3Q17, the company’s Oncology Systems business witnessed a gross margin improvement of 200 basis points to reach 48.1% of the segment’s total […]

    By Sarah Collins
  • uploads///PERFORMANCE
    Earnings Report

    Key Highlights of Varian Medical Systems’ Fiscal 2Q17 Earnings

    On April 26, 2016, Varian Medical Systems (VAR) released its 2Q17 earnings. VAR beat consensus estimates for revenues in 2Q17 by ~0.8% and reported in-line earnings per share.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Varian Medical Systems: Analyzing Its Stock Performance

    Varian Medical Systems (VAR) was trading at $102.7 on June 29, 2017. It has a 50-day moving average of $100.4 and a 200-day moving average of $88.8.

    By Sarah Collins
  • uploads/// Bottom
    Real Insights

    Could It Be Time to Buy US Domestic Moats?

    VanEck U.S. Domestic Moats: Buy Buy Baby (Contd..) It’s been a wild ride for pharmaceutical and biotech companies since last year’s U.S. presidential election, but Morningstar’s economic moat and valuation research within both industries benefited the U.S. Moat Index as several of the top drivers of performance came from within those industries. Materials firm Compass […]

    By VanEck
  • uploads///segment revenues
    Earnings Report

    How Did Danaher’s Operating Segments Fare in 4Q16?

    Currently, Danaher (DHR) reports its revenue under four operating segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.

    By Sheldon Krieger
  • uploads///stock
    Earnings Report

    Why Danaher Stock Rose after Its 4Q16 Results

    Danaher Corporation (DHR) announced its 4Q16 and 2016 earnings results before the market opened on January 31, 2017. Let’s take a look.

    By Sheldon Krieger
  • uploads///stock price
    Earnings Report

    What Factors Could Drive Danaher Stock in 2017?

    Danaher Corporation (DHR) will announce its 4Q16 earning results before the market opens on January 31, 2017. What should we expect?

    By Sheldon Krieger
  • uploads/// Wide Moat
    Company & Industry Overviews

    Analyzing Morningstar’s Economic Moat Rating

    Morningstar first began rating companies in 2002 according to the strength and longevity of their competitive advantages.

    By VanEck
  • uploads///A VanEckk chart
    Company & Industry Overviews

    Moat Investing: Staying Ahead of the Competition

    Moat companies offer long-term outperformance compared to benchmarks.

    By VanEck
  • uploads///PERFORMANCE
    Company & Industry Overviews

    Varian Medical Systems Attempts to Improve Its Performance Growth

    Varian Medical Systems (VAR) raised its guidance for fiscal 2016 in the view of higher-than-expected 3Q16 results reported on July 27.

    By Sarah Collins
  • uploads///part
    Company & Industry Overviews

    How Are Danaher’s Returns Compared to Its Industry Peers’?

    Danaher’s ROIC fell steadily from 15.5% in 2006 to 8.5% in 2015, indicating that it has probably had fewer high return reinvestment opportunities since then.

    By Shannon Black
  • uploads///oncology megatrends
    Company & Industry Overviews

    What’s Varian’s Product Strategy for Its Oncology Business?

    Varian Medical Systems’ (VAR) radiation oncology business has a strong foothold around the world.

    By Sarah Collins
  • uploads///market share
    Company & Industry Overviews

    How Is Varian Positioned in the Particle Therapy Business?

    Varian Medical Systems (VAR) had gross orders value of $310 million in 2015.

    By Sarah Collins
  • uploads///growth strategy
    Company & Industry Overviews

    Growth Strategies Driving Varian Medical Systems’ Revenue

    Varian Medical Systems has ventured into the proton therapy business and has a huge product pipeline in this area. The company generated approximately $300 million through its proton therapy business in 2015.

    By Sarah Collins
  • uploads///radiotherapy gaps
    Company & Industry Overviews

    Varian Medical Systems’ Growth Potential in Radiation Oncology

    Varian Medical Systems’ next big technology innovation will be high-definition radiotherapy, which is an intelligent treatment delivery system that aims to achieve 100% radiation exposure for the tumor.

    By Sarah Collins
  • uploads///business segments
    Company & Industry Overviews

    Where Does Varian Medical Systems Get Most of Its Revenue?

    Varian Medical Systems’ Imaging Components segment accounts for approximately 19% of the company’s total revenue. The segment reported a revenue decline of ~10% in 2015.

    By Sarah Collins
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    XLV’s Mid-October Performance amid Falling Biotech Stocks

    On October 20, biotech stocks again witnessed a sell-off, causing the major biotech ETFs to finish the day in the red. XLV similarly fell by 1.55%.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Top Ten Mid-Cap Stocks Outperformed SPY on October 12

    Varian Medical Systems (VAR) fell by 1.5% and closed at $76.82 on October 12. The stock fell on profit booking, breaking its three-day upward trend.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.